NCT02275065View on ClinicalTrials.gov

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

October 24, 2014

Primary Completion Date

January 23, 2015

Study Completion Date

January 29, 2015

Conditions

HIV-1 Infection

Interventions

DRUG

Bictegravir

Bictegravir tablet(s) administered orally once daily

DRUG

Placebo

Placebo to match bictegravir administered orally once daily

Trial Locations (16)

Unknown

Berkeley

Davis

Long Beach

Los Angeles

San Francisco

Washington D.C.

Fort Lauderdale

Orlando

Vero Beach

West Palm Beach

Atlanta

Berkley

Newark

Santa Fe

Dallas

Seattle

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY